By Menopause Reviewed Editorial Team | Last reviewed: May 2026
Dietary supplements account for roughly 94 percent of the total menopause treatment market, which Grand View Research valued at approximately $17.8 billion in 2024. Products marketed for hot flashes, night sweats, mood, sleep, and vaginal health fill pharmacy shelves with claims that routinely outpace the evidence.
Supplement companies are not required to prove efficacy before selling a product in the United States — products reach consumers first, and evidence follows years later, if at all. This article applies a consistent evidence rubric to the major supplement categories marketed for menopause, covers the industry quality problem that affects all of them, and identifies the narrow circumstances where supplementation makes evidence-based sense.
The Evidence Rubric
Each category below receives one of four grades: High (multiple RCTs plus meta-analyses showing consistent benefit); Moderate (some RCTs with significant results, but mixed findings or methodological limitations); Low (primarily preclinical or observational data); or None (anecdotal or marketing claims only). This mirrors the Level I–III classification used by The Menopause Society (formerly NAMS) in its 2023 nonhormone therapy position statement, which reviewed most of the supplements below and found insufficient evidence to recommend any of them for vasomotor symptoms.
The Supplement Categories
Black Cohosh — Evidence: Low
Black cohosh (Cimicifuga racemosa) is among the most studied botanical supplements for menopause, and the result of that study is telling. The 2012 Cochrane systematic review found insufficient evidence to support its use for vasomotor symptoms, with no statistically significant difference from placebo in hot flush frequency. NAMS 2023 classifies it Level I: not recommended.
The NIH LiverTox database documents more than 50 cases of clinically apparent liver injury linked to black cohosh products, ranging from asymptomatic enzyme elevations to acute liver failure. The European Medicines Agency identified 42 cases and required hepatotoxicity advisory labeling. Causality remains contested — many cases involved poorly documented exposures or possible adulteration — but the signal warrants caution in women with existing liver conditions or concurrent hepatotoxic medications.
Red Clover Isoflavones — Evidence: Moderate (Limited)
Red clover (Trifolium pratense) contains biochanin A, formononetin, genistein, and daidzein. A 2021 meta-analysis in Nutrients covering eight RCTs found a statistically significant reduction in daily hot flush frequency (WMD −1.73; 95% CI −3.28 to −0.18; p=0.0292), most pronounced at 80 mg/day or more. Heterogeneity was substantial (I² = 87%) and effect sizes modest. A 2018 meta-analysis in Maturitas (12 RCTs; 1,284 women) found more consistent lipid benefits than vasomotor effects. The broader phytoestrogen evidence reviewed by NAMS was deemed mixed and insufficient to recommend.
Soy Isoflavones — Evidence: Moderate (Population-Dependent)
Soy isoflavones have a larger clinical evidence base than most botanical supplements. A 2019 systematic review and meta-analysis in Nutrients found reductions in vasomotor symptom frequency and severity — with a critical caveat: benefit was substantially larger in equol producers than in non-producers. Equol is a daidzein metabolite produced by gut bacteria; approximately 25–30 percent of Western women produce it, versus roughly 50–60 percent in Asian populations with lifelong soy exposure. This likely explains why Asian-cohort trials show stronger effects than Western trials. NAMS categorizes soy foods, soy extracts, and equol as Level II: not recommended for VMS due to mixed evidence.
Phytoestrogens Broadly: What Genistein and Daidzein Actually Do
Genistein and daidzein bind estrogen receptors with pronounced selectivity for ERβ over ERα. A 2025 review in the International Journal of Molecular Sciences describes them as SERM-like — tissue-specific agonism or antagonism depending on cellular context — with stronger effects in bone and cardiovascular tissue than in reproductive tissue. For vasomotor symptoms, clinical reductions are modest and substantially smaller than hormone therapy. For bone, multiple RCTs demonstrate attenuation of mineral density loss at 50 mg/day or more over 12 months. Phytoestrogens do not appear to increase hormone-sensitive cancer risk at dietary intake levels.
Maca — Evidence: Low
The clinical evidence for maca (Lepidium meyenii) consists primarily of small Peruvian trials with significant methodological limitations. A 2013 pilot study in the International Journal of Biomedical Science found reduced menopausal discomfort scores but noted a "distinctive, positive placebo effect" complicating interpretation. No large independently replicated RCTs exist. NAMS classifies maca Level II: not recommended. Maca does not contain phytoestrogens; its proposed adrenal-related mechanism is not yet characterized in rigorous clinical studies.
Evening Primrose Oil — Evidence: None to Low
EPO is marketed for hot flashes on the premise that gamma-linolenic acid modulates prostaglandin pathways. A 2024 systematic review in the Journal of Menopausal Medicine covering six RCTs (450 women) found no statistically significant difference from placebo in hot flush frequency or duration; evidence grading was moderate to low. The American Academy of Family Physicians similarly concluded evidence does not support EPO for menopause. NAMS: Level II, not recommended.
Vitamin D — Evidence: High for Deficiency Correction; Low for Symptom Relief in Replete Women
The evidence for vitamin D depends entirely on baseline status. Deficiency — serum 25-hydroxyvitamin D below 20 ng/mL — is common in postmenopausal women and associated with reduced bone mineral density, increased fracture risk, and worse menopausal symptoms, per a 2023 review in Frontiers in Physiology. The 2022 EMAS position statement is clear: supplementation co-administered with calcium may reduce fracture risk when deficiency is present, but vitamin D is not recommended for postmenopausal symptom relief or cardiovascular or cancer risk reduction in replete women — a finding the Women's Health Initiative corroborated. Serum testing is the appropriate first step; correcting documented deficiency is well-supported, supplementing to supraphysiologic levels is not.
Magnesium — Evidence: Moderate for Sleep and Mild Anxiety; Limited for Menopause-Specific Symptoms
Magnesium has the most credible micronutrient evidence base for sleep and anxiety. A 2024 systematic review in Cureus found generally positive RCT results for mild insomnia and anxiety, particularly in those with low baseline magnesium status. A double-blind RCT by Abbasi et al. (2012) in older adults with insomnia found magnesium significantly reduced sleep onset latency (p=0.02), improved sleep efficiency (p=0.03), and lowered serum cortisol (p=0.008) versus placebo. A 2024 RCT in the Medical Research Archives found significant improvements in sleep quality and deep sleep.
The key limitation: no RCT has specifically enrolled perimenopausal women and tested magnesium for menopause-pattern sleep disruption as a primary outcome. Mechanistically, magnesium is an NMDA receptor antagonist that regulates melatonin synthesis — biological plausibility is high. But the translational gap to menopause-specific application has not been formally bridged.
Omega-3 EPA/DHA — Evidence: Moderate for Cardiovascular; Low for Vasomotor Symptoms
The cardiovascular evidence for omega-3s is among the strongest in clinical nutrition. A 2021 meta-analysis in EClinicalMedicine covering 38 RCTs (149,051 participants) found omega-3 supplementation reduced cardiovascular mortality (RR 0.94 for EPA+DHA; 0.82 for EPA alone) and non-fatal myocardial infarction — directly relevant to postmenopausal women facing an accelerating cardiovascular risk curve. For menopause-specific symptoms, however, a systematic review of omega-3 supplementation in menopausal women found no significant reduction in hot flush frequency or sleep quality; NAMS classifies omega-3 for VMS as Levels I–II: not recommended. The cardiovascular benefit is strongest in women with low dietary fish intake.
Ashwagandha — Evidence: Low to Moderate (Emerging)
Ashwagandha (Withania somnifera) root extract has a preliminary but promising evidence base in menopausal women. A 2026 randomized, double-blind, placebo-controlled trial in Frontiers in Reproductive Health (60 women, 56 days) found significantly reduced Menopause Rating Scale scores across all domains (p<0.0001), along with reduced FSH and LH and increased estradiol and progesterone — results that require replication in larger trials. The broader literature shows consistent cortisol reduction in stressed adults across multiple RCTs, providing mechanistic plausibility via HPA axis modulation rather than direct estrogen receptor activity. Women with thyroid conditions should consult a clinician before use.
Calcium — Brief Note (Bone Health Context)
Calcium is addressed more fully in the bone health article in this series. A pooled meta-analysis of 11 RCTs by Bolland et al. (The BMJ, 2010) associated supplemental calcium with approximately a 30 percent increased risk of myocardial infarction (RR 1.27; 95% CI 1.01–1.59; p=0.038). A 2023 meta-analysis found no such association, leaving the question unresolved — which is why current guidelines favor dietary calcium over supplements where cardiovascular risk is a concern. Fracture risk reduction is most supported when calcium is co-administered with vitamin D in women with genuinely inadequate dietary intake.
DIM (Diindylmethane) and I3C (Indole-3-Carbinol) — Evidence: Low
DIM — the primary in vivo metabolite of indole-3-carbinol from cruciferous vegetables — is marketed as an estrogen "balancer" that shifts metabolism toward the 2-hydroxyestrone (2-OHE1) pathway and away from 16α-hydroxyestrone (16-OHE1). The mechanistic activity is real: DIM does alter urinary estrogen profiles via CYP1A1 and CYP1A2 induction. A 2025 study in Menopause found that postmenopausal women taking DIM concurrently with a transdermal estradiol patch had significantly lower total estrogen exposure compared to patch-only users — a drug-supplement interaction with direct clinical implications for hormone therapy effectiveness. Women on HRT taking DIM should discuss this with their prescribing clinician. The broader claim that a favorable 2/16-OHE1 ratio reduces breast cancer risk in healthy women is not established by prospective outcome data, and DIM does not relieve vasomotor symptoms.
Probiotics for Vaginal and Urinary Tract Health — Evidence: Moderate (Strain-Specific)
Estrogen withdrawal reduces vaginal Lactobacillus dominance, creating a well-characterized mechanism for dysbiosis, genitourinary syndrome, and recurrent UTI. A randomized, double-blind phase 2 trial in Clinical Infectious Diseases (2011) found intravaginal L. crispatus CTV-05 reduced recurrent UTI rates by approximately 50 percent versus placebo. A 2023 Japanese study in Frontiers in Microbiology found L. crispatus vaginal suppositories reduced recurrent cystitis episodes by 62 percent in a postmenopausal cohort. Strain specificity is critical: generic probiotic blends not specifying Lactobacillus crispatus do not carry this evidence base.
The Supplement Industry Quality Problem
Evidence grade is only one dimension of the problem. What is actually inside the capsule is the other.
In February 2015, the New York Attorney General required GNC, Target, Walmart, and Walgreens to remove store-brand herbal supplements after DNA testing found only 21 percent of products contained DNA matching the labeled botanical. The methodology was later challenged — DNA barcoding performs poorly on extracted botanical material from which cellular DNA has been removed — and the primary research paper was retracted in 2024 after the University of Guelph found evidence of data fabrication. The methodological dispute is legitimate; the underlying quality problem it exposed is not. Supplement manufacturing quality varies significantly, and contamination and mislabeling are documented occurrences.
Two third-party programs provide meaningful assurance. The USP Verified mark requires annual facility audits and independent product testing. NSF International (NSF/ANSI 173) tests for label accuracy and contaminants. Neither certifies efficacy, but both verify that label claims reflect actual contents — a baseline that matters in an industry where it is not guaranteed.
When Supplements Do Make Sense
Despite the largely negative review, legitimate use cases exist:
Documented deficiency correction. Vitamin D deficiency is common and correctable. Low magnesium status may worsen sleep and anxiety. Omega-3 is reasonable for women with low fish intake and elevated cardiovascular risk. These are general nutritional gaps with evidence-supported corrections, not menopause-specific interventions.
Strain-specific probiotics for recurrent UTI. Women with post-menopausal recurrent UTI have a biologically plausible mechanism and emerging clinical evidence for L. crispatus-specific delivery — warranting clinician discussion rather than self-directed retail purchasing.
Adjunctive phytoestrogens for non-HRT candidates. Soy or red clover isoflavones at adequate doses represent modest but real benefits for some women, particularly equol producers, with acceptable safety profiles. These are not substitutes for hormone therapy.
No supplement reviewed here approaches the evidence standing of hormone therapy for vasomotor symptoms, or of CBT and clinical hypnosis — both of which carry Level I recommendations in the 2023 NAMS nonhormone position statement.
Beyond Supplements: Peptide Therapy
For women whose symptom burden remains high after evidence-based supplementation and lifestyle changes have been optimized, peptide therapy is increasingly discussed in functional medicine spaces. The clinical evidence base for peptides in menopausal women is significantly thinner than for the supplements reviewed above — as of early 2026, no randomized controlled trials have examined research-grade peptides specifically for perimenopause or postmenopause symptoms. The biology is mechanistically interesting in some cases, but the translation to human clinical benefit has not been established. A full review of the peer-reviewed evidence for specific peptides is available in the peptide article in this series.